Summary of Key Performance
Although Yuwell Medical's performance in the first half of 2026 shifted from "dual growth" last year to a period of "adjustment and consolidation," the company has managed to achieve new growth through proactive investment in product promotion and expansion into overseas markets. The core profit reached 761 million yuan, and cash flow remained stable. Sales of new products such as Continuous Glucose Monitoring (CGM) devices, home ventilators, and Automated External Defibrillators (AEDs) increased rapidly. Overseas revenue grew by 35.76% year-on-year, becoming a significant driver of growth. Additionally, the company has accelerated its "wearable technology" strategy, transitioning from a hardware manufacturer to a health management service provider.
1. Stabilized Cash Flow and Investment Returns During the Adjustment Period
In the first half of the year, Yuwell's revenue was 4.569 billion yuan, with a core profit of 761 million yuan. Although the growth wasn't as substantial as last year, cash flow was strong, at 1.182 billion yuan (a 1.31% increase year-on-year), indicating that the company is generating real profits. The key is that the funds were invested in strategic areas: product promotion and overseas market expansion. These efforts paid off, with rapid sales of CGM devices and home ventilators, and a significant boost in revenue due to the expansion of the AED product line.
2. New Products as Growth Drivers
Three key areas have driven growth:
1. Respiratory Therapy: Sales of home ventilators have increased despite the overall market downturn, thanks to products like the ET5-25 dual-level ventilator and the Pocket X portable model, which meet the demand for sleep-related respiratory diseases management.
2. Glucose Management: The CGM business has doubled in revenue, reflecting the growing demand from diabetic patients for real-time blood glucose monitoring. Domestic CGM technology (sensors + AI) is advancing, offering significant potential for further growth.
3. Emergency Services: The AED segment saw the fastest growth, with revenue increasing by 50.3% year-on-year. Yuwell has obtained new AED certifications, expanding its product range for home, public, and mobile emergencies, and has integrated services including equipment, maintenance, and training, which has increased both revenue and profits.
3. Overseas Market Expansion Becomes a New Growth Driver
Yuwell's globalization strategy is bearing fruit: Overseas sales reached 824 million yuan, a 35.76% increase year-on-year, accounting for 18% of total revenue. The company has made progress in European and American markets, and continued stable growth in Southeast Asia and South America. It has also established subsidiaries in the United States, Indonesia, and Brazil, with localized teams for marketing and services.
- Regional Breakthroughs: Yuwell has successfully entered these markets and is expanding its product range.
- Product Expansion: The CGM products have obtained EU CE certification, allowing entry into the European market, and the oxygen generator business is making significant progress in Europe and America, potentially becoming another growth driver.
4. Transitioning to a "Health Manager" with Wearable Technology
Yuwell's chairman's vision of "hospitalization for home use and wearables for home use" is becoming a reality:
- The Yuwell Watch A1 wrist device can measure blood pressure, blood sugar, and oxygen levels, covering essential physiological indicators.
- Future focus will be on "metabolic management," starting with CGM and expanding to尿酸 and lactic acid monitoring. The "Annaicang" app will serve as an AI platform to connect users with their devices, creating a closed-loop for monitoring, early warning, and intervention.
5. Continuous Investment in R&D for Long-Term Growth
Yuwell continues to invest heavily in R&D, spending 306 million yuan in the first half of the year (a 3.8% increase year-on-year), with a total investment of over 3.2 billion yuan since 2020. These investments have supported the development of innovative products (such as advanced CGM sensors and AI algorithms), maintaining the company's competitive edge.
Overall, although Yuwell Medical is in an adjustment phase, new growth drivers are emerging. The company's transition from a hardware manufacturer to a health management service provider is promising. (Note: This analysis does not constitute investment advice.)